Minerva Neurosciences, Inc. (NERV) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -35.14M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 15.54M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-35.14M | (m) | (m) | $15.54M | (m) | (m) |
| 2026-03-31 | $-27.87M | (m) | (m) | $9.65M | (m) | (m) |
| 2025-12-31 | $-15.10M | (m) | (m) | $5.76M | (m) | (m) |
| 2025-09-30 | $-14.64M | (m) | (m) | $5.57M | (m) | (m) |
| 2025-06-30 | $-16.17M | (m) | (m) | $6.53M | (m) | (m) |
| 2025-03-31 | $-19.07M | (m) | (m) | $9.09M | (m) | (m) |
| 2024-12-31 | $-21.85M | $0.00 | (m) | $11.90M | (m) | (m) |
| 2024-09-30 | $-24.50M | (m) | (m) | $14.64M | (m) | (m) |
| 2024-06-30 | $-26.21M | (m) | (m) | $16.19M | (m) | (m) |
| 2024-03-31 | $-24.45M | (m) | (m) | $14.22M | (m) | (m) |
| 2023-12-31 | $-23.12M | $0.00 | (m) | $12.71M | (m) | (m) |
| 2023-09-30 | $-21.02M | (m) | (m) | $11.17M | (m) | (m) |
| 2023-06-30 | $-20.15M | (m) | (m) | $10.10M | (m) | (m) |
| 2023-03-31 | $-22.59M | (m) | (m) | $12.34M | (m) | (m) |
| 2022-12-31 | $-25.23M | $0.00 | (m) | $14.65M | (m) | (m) |
| 2022-09-30 | $-41.54M | (m) | (m) | $30.21M | (m) | (m) |
| 2022-06-30 | $-43.85M | (m) | (m) | $32.35M | (m) | (m) |
| 2022-03-31 | $-45.85M | (m) | (m) | $33.74M | (m) | (m) |
| 2021-12-31 | $-45.37M | $0.00 | (m) | $32.04M | (m) | (m) |
| 2021-09-30 | $-31.29M | $0.00 | (m) | $16.84M | (m) | (m) |
| 2021-06-30 | $-31.86M | $0.00 | (m) | $16.97M | (m) | (m) |
| 2021-03-31 | $6.61M | $0.00 | (m) | $17.22M | (m) | (m) |
| 2020-12-31 | $1.85M | $0.00 | (m) | $22.04M | (m) | (m) |
| 2020-09-30 | $-23.22M | $0.00 | (m) | $47.01M | (m) | (m) |
| 2020-06-30 | $-29.41M | $0.00 | (m) | $52.05M | (m) | (m) |
| 2020-03-31 | $-71.82M | $0.00 | (m) | $54.60M | (m) | (m) |
| 2019-12-31 | $-75.87M | $0.00 | (m) | $58.12M | (m) | (m) |
| 2019-09-30 | $-57.13M | $0.00 | (m) | $38.61M | (m) | (m) |
| 2019-06-30 | $-55.27M | $0.00 | (m) | $37.30M | (m) | (m) |
| 2019-03-31 | $-55.30M | $0.00 | (m) | $38.05M | (m) | (m) |
| 2018-12-31 | $-51.73M | $0.00 | (m) | $34.89M | (m) | (m) |
| 2018-09-30 | $-47.63M | $0.00 | (m) | $32.42M | (m) | (m) |
| 2018-06-30 | $-46.62M | (m) | (m) | $33.01M | (m) | (m) |
| 2018-03-31 | $-43.43M | (m) | (m) | $31.09M | (m) | (m) |
| 2017-12-31 | $-41.17M | $0.00 | (m) | $30.26M | (m) | (m) |
| 2017-09-30 | $-40.88M | (m) | (m) | $30.21M | (m) | (m) |
| 2017-06-30 | $-37.70M | (m) | (m) | $27.11M | (m) | (m) |
| 2017-03-31 | $-32.92M | (m) | (m) | $22.68M | (m) | (m) |
| 2016-12-31 | $-30.19M | (m) | (m) | $20.44M | (m) | (m) |
| 2016-09-30 | $-29.15M | (m) | (m) | $20.20M | (m) | (m) |
| 2016-06-30 | $-26.62M | (m) | (m) | $18.18M | (m) | (m) |
| 2016-03-31 | $-27.99M | (m) | (m) | $19.95M | (m) | (m) |
| 2015-12-31 | $-26.11M | (m) | (m) | $18.53M | (m) | (m) |
| 2015-09-30 | $-25.36M | (m) | (m) | $15.24M | (m) | (m) |
| 2015-06-30 | $-46.81M | (m) | (m) | $36.21M | (m) | (m) |
| 2015-03-31 | $-58.13M | (m) | (m) | $46.28M | (m) | (m) |
| 2014-12-31 | $-54.87M | (m) | (m) | $42.91M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-5.53M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-3.17M | (m) | (m) | $708.49K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |